GO
Loading...

Vivus Inc

More

  • Vivus reports 4Q loss Tuesday, 24 Feb 2015 | 5:12 PM ET

    MOUNTAIN VIEW, Calif. _ Vivus Inc. on Tuesday reported a loss of $25.4 million in its fourth quarter. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of 24 cents per share. Analysts expected $23.2 million, according to Zacks.

  • Feb 20- Sarissa Capital Management LP kicked off a proxy battle with Ariad Pharmaceuticals Inc, demanding the retirement of Harvey Berger, the drugmaker's chief executive and principal founder, as the company struggles with poor sales of its only drug on the market. Ariad's blood cancer drug, Iclusig, has failed to live up to sales expectations after the U.S. Food...

  • Feb 20- Sarissa Capital Management LP kicked off a proxy battle with Ariad Pharmaceuticals Inc on Friday, demanding the retirement of Harvey Berger, the drugmaker's chief executive and principal founder. The hedge fund, Ariad's largest shareholder with a 6.87 percent stake, according to Thomson Reuters data, has been negotiating Berger's exit with some of...

  • Jan 7- Zafgen Inc said a mid-stage study showed its experimental drug reduced weight in patients obese due to damage to a part of the brain. Vivus Inc's Qsymia, Arena Pharmaceuticals Inc's Belviq and Orexigen Therapeutics Inc's Contrave appear to work by signaling the brain, but their exact mechanism of action is unknown. The U.S. Food and Drug Administration...

  • FDA approves Novo Nordisk's injection for obesity Tuesday, 23 Dec 2014 | 5:14 PM ET

    Dec 23- The U.S. health regulator approved a formulation of Novo Nordisk's diabetes drug, liraglutide, for treating patients of obesity, a disease that affects one in three Americans. Saxenda's rivals include Vivus Inc's Qsymia and Arena Pharmaceuticals Inc's Belviq, which are taken orally. A study showed that half the patients given Saxenda lost at least 5...

  • Dec 19- European regulators recommended the approval of Orexigen Therapeutics Inc's diet pill, which could become the first prescription medicine for obesity to be approved in the European Union in nearly a decade. The drug, sold as Contrave by partner Takeda Pharmaceutical Co in the United States, will be marketed as Mysimba in Europe. The third obesity...

  • The drug, developed by Vivus Inc, is marketed in the United States and Canada by Auxilium Pharmaceuticals Inc. Vivus' stock was up about 13 percent at $4.40 in afternoon trading.

  • The drug was developed by Auxilium Pharmaceuticals Inc and Vivus Inc.. Vivus owns the worldwide development and commercial rights to Stendra for use in sexual dysfunction, with the exception of certain Asian countries in the Pacific Rim.

  • NEW YORK, Sept 18- U.S. stocks were higher in afternoon trading on Thursday, with the S&P 500 hitting a record peak a day after the U.S.

  • The drug, developed by Vivus Inc, is marketed in the United States and Canada by Auxilium Pharmaceuticals Inc. Vivus' stock was up about 13 percent at $4.40 in afternoon trading.

  • US STOCKS-Dow, S&P hit record as financials climb Thursday, 18 Sep 2014 | 1:14 PM ET

    NEW YORK, Sept 18- U.S. stocks were higher in afternoon trading Thursday, with the Dow and S&P 500 hitting fresh record highs after the U.S. Goldman Sachs, up 1.6 percent to $187.84, was the top boost to the Dow.

  • US STOCKS-S&P hits record on Fed support; financials lead Thursday, 18 Sep 2014 | 11:42 AM ET

    NEW YORK, Sept 18- U.S. stocks were rising in late morning trading on Thursday, with the S&P 500 hitting a record high a day after the U.S. However, the central bank's outlook included forecasts for higher-than-expected rates in 2015 and 2016, which helped financial stocks lead gains on Wall Street.

  • The largest percentage gainer on the New York Stock Exchange was Penn West Petroleum, up 11.54 percent, while the largest decliner was Pier 1 Imports, down 17.57 percent a day after it slashed its full-year earnings forecast.

  • *Futures up: Dow 44 pts, S&P 6 pts, Nasdaq 13 pts. NEW YORK, Sept 18- U.S. stocks were set to rise at the open on Thursday, with the S&P 500 on track to test resistance at its record high a day after the U.S.

  • Sept 18- An erectile dysfunction drug that reduces by half the time patients need to take the pill before sexual activity has been approved by the U.S. Food and Drug Administration.

  • Here's a new way to lose weight Thursday, 11 Sep 2014 | 8:08 AM ET

    U.S. regulators are greenlighting a new weight-loss drug called Contrave, the third in a string of approvals for anti-obesity treatments.

  • Long-awaited diet pill gets U.S. approval Wednesday, 10 Sep 2014 | 9:00 PM ET

    Sept 10- A new diet pill Contrave got approval to be sold in the United States on Wednesday, only the third obesity treatment in more than a decade to win approval from the Food and Drug Administration.

  • WASHINGTON, Sept 9- Novo Nordisk's drug liraglutide appears effective in treating obesity, though safety questions remain, according to a preliminary assessment by reviewers at the U.S. Food and Drug Administration.

  • You’ve got obesity all wrong: Zafgen CEO Tuesday, 19 Aug 2014 | 10:45 AM ET

    Despite the fact that more than a third of U.S. adults are obese, it's been an uphill battle for developers of obesity treatments.

  • Lightning Round: Akamai, GE & more Tuesday, 15 Jul 2014 | 6:49 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.